

## Research Article

# Identification of Keratinocyte Differentiation-Involved Genes for Metastatic Melanoma by Gene Expression Profiles

Kezhu Li, Shu Guo, Shuang Tong, Qiang Sun, Shifeng Jin, Bingran Qi, Yining Shao, and Nan Xu 

Department of Plastic Surgery, The First Hospital of China Medical University, Shenyang, 11000 Liaoning Province, China

Correspondence should be addressed to Nan Xu; 20071099@cmu.edu.cn

Received 28 October 2021; Accepted 2 December 2021; Published 28 December 2021

Academic Editor: Jun Yang

Copyright © 2021 Kezhu Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** Melanoma is the deadliest type of skin cancer. Until now, its pathological mechanisms, particularly the mechanism of metastasis, remain largely unknown. Our study on the identification of genes in association with metastasis for melanoma provides a novel understanding of melanoma. **Methods.** From the Gene Expression Omnibus (GEO) database, the gene expression microarray datasets GSE46517, GSE7553, and GSE8401 were downloaded. We made use of R aiming at analyzing the differentially expressed genes (DEGs) between metastatic and nonmetastatic melanoma. R was also used in differentially expressed miRNA (DEM) data mining from GSE18509, GSE19387, GSE24996, GSE34460, GSE35579, GSE36236, and GSE54492 datasets referring to Li's study. Based on the DEG and DEM data, we performed functional enrichment analysis through the application of the DAVID database. Furthermore, we constructed the protein-protein interaction (PPI) network and established functional modules by making use of the STRING database. Through making use of Cytoscape, the PPI results were visualized. We predicted the targets of the DEMs through applying TargetScan, miRanda, and PITA databases and identified the overlapping genes between DEGs and predicted targets, followed by the construction of DEM-DEG pair network. The expressions of these keratinocyte differentiation-involved genes in Module 1 were identified based on the data from TCGA. **Results.** 239 DEGs were screened out in all 3 datasets, which were inclusive of 21 positively regulated genes and 218 negatively regulated genes. Based on these 239 DEGs, we finished constructing the PPI network which was formed from 225 nodes and 846 edges. We finished establishing 3 functional modules. And we analyzed 92 overlapping genes and 26 miRNA, including 11 upregulated genes targeted by 11 negatively regulated DEMs and 81 downregulated genes targeted by 15 positively regulated DEMs. As proof of the differential expression of metastasis-associated genes, eleven keratinocyte differentiation-involved genes, including LOR, EVPL, SPRR1A, FLG, SPRR1B, SPRR2B, TGM1, DSP, CSTA, CDSN, and IVL in Module 1, were obviously downregulated in metastatic melanoma tissue in comparison with primary melanoma tissue based on the data from TCGA. **Conclusion.** 239 melanoma metastasis-associated genes and 26 differentially expressed miRNA were identified in our study. The keratinocyte differentiation-involved genes may take part in melanoma metastasis, providing a latent molecular mechanism for this disease.

## 1. Introduction

Melanoma is the cells' neoplasm, starting in skin cells, namely, melanocytes [1]. Environmental factors, such as ultraviolet light exposure, are regarded as the main reason causing melanoma [2]. This tumor is mainly in the skin or adjacent to the skin and spreads throughout the body [3], with a dramatic increase in global incidence in the last few decades [4]. Metastasis, the most important characteristic

of malignant tumors, is the primary reason for deaths in related to melanoma [5]. What is more, for patients with advanced melanoma, there are still no satisfactory treatments, which involve complicated changes in multiple genes and signaling pathways. Thus, investigating the latent molecular mechanisms of metastasis in melanoma is of great significance.

Recently, microarray technology has a wide range of applications in studying gene alterations in cancer

recurrence, metastasis, tumorigenesis, drug resistance and identification of biomarkers for tumor prognosis, and diagnosing and treating the tumor [6–8]. By making use of RNA-sequencing analysis on many genes, as reported, RNAs, which contain long noncoding RNAs (lncRNAs), messenger RNAs (mRNAs), and miRNAs, and proteins have a critical influence on progression, melanoma initiation, and recurrence. MicroRNA is a type of noncoding RNA with a length of 18-25 nucleotides, which serves as a posttranscriptional regulator [9]. miRNA plays a role in human diseases by binding to the target mRNA in the 3'-untranslated region (3'-UTR). Previous reports have shown that miR-182 inhibits the proliferation of malignant melanoma cells through RECK [10]. Androgen receptor (AR) promotes melanoma metastasis by altering miRNA-539-3p/USP13/MITF/AXL signal [11]. In our study, we gained 3 mRNA microarrays and 7 miRNA microarrays aiming at analyzing the DEGs and DEMs between primary melanoma and metastatic melanoma tissue samples. We applied functional enrichment and network analysis. The results demonstrated latent molecular mechanisms on metastatic melanoma.

## 2. Material and Methods

**2.1. Data Collection.** We gained the GSE46517, GSE7553, and GSE8401 gene expression profiles and GSE18509, GSE19387, GSE24996, GSE34460, GSE35579, GSE36236, and GSE54492 miRNA expression profile from Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo/>) [12]. The GSE46517 dataset included 8 normal skin samples, 9 nevus samples, 73 metastatic melanoma samples, and 31 primary melanoma samples [13]. GSE7553 was made up of 87 samples, including 5 normal samples, 15 basal cell carcinoma samples, 16 primary melanoma samples, 11 squamous cell carcinoma samples, and 40 metastatic melanoma samples [14]. GSE8401 contained 83 samples, 52 metastatic melanoma samples, and 31 primary melanoma samples included [15]. For these datasets, we screened out and analyzed metastatic melanoma samples. And we retrieved primary melanoma samples as control. Meanwhile, we collected seven miRNA expression profiles in total, which were inclusive of 82 metastatic and 87 nonmetastatic samples [12].

**2.2. Screening DEGs and DEMs.** We conducted the DEG and DEM analysis through the application of the limma software package in Bioconductor package (<http://www.bioconductor.org/packages/release/bioc/html/limma.html>) [16] in R software. In DEG analysis, our cutoff value was  $p < 0.01$  and  $|\text{fold change (FC)}| > 1.5$ , and we made use of  $\text{FDR} < 0.05$  in DEM analysis [12]. Unique DEGs and DEMs were selected.

**2.3. GO and Pathway Analysis of DEGs.** As a predominant bioinformatics initiative, Gene Ontology (GO: <http://www.geneontology.org/>) [17] contains the most annotations under three headings: molecular function (MF), biological processes (BP), and cellular component (CC), while we performed the Kyoto Encyclopedia of Genes and Genomes (KEGG: <http://www.genome.ad.jp/KEGG>) [18] pathway




FIGURE 1: Identification of DEGs in mRNA expression profiling datasets GSE46517, GSE7553, and GSE8401.

enrichment analysis for the investigation of the signaling pathways that were in association with the unique DEGs. We made GO and KEGG pathway analysis through the Database for Annotation Visualization and Integrated Discovery (DAVID: <http://www.david.ncifcrf.gov/>) for the identification of the DEGs' biological significance [19]. We regarded  $\text{FDR} < 0.01$  and  $\text{gene count} > 2$  as statistical significance.

**2.4. Protein-Protein Interaction (PPI) Network Construction.** We first mapped the DEGs to the Search Tool for the Retrieval of Interacting Genes (STRING) (<http://www.cytoscape.org/>) [20] aiming at assessing functional associations among them. Then, through making use of the Molecular Complex Detection (MCODE), an app of Cytoscape software, we identified the functional modules of the PPI network.

**2.5. miRNA Target Prediction and DEM-DEG Network Construction.** We gained the predicted targets of miRNAs from TargetScan ([http://www.targetscan.org/vert\\_72/](http://www.targetscan.org/vert_72/)) [21], miRanda (<http://www.microrna.org/microrna/home.do>) [22], and PITA ([http://genie.weizmann.ac.il/pubs/mir07/mir07\\_data.html](http://genie.weizmann.ac.il/pubs/mir07/mir07_data.html)) databases [23]. The target genes which were predicted in at least two datasets were selected for the construction of the DEM-DEG pair network.

**2.6. Validation of Differential Expression of Metastasis-Associated Genes.** UALCAN, a comprehensive web resource for analyzing cancer OMICS data (TCGA and MET500), was used to validate the expression of 11 metastasis-associated genes enriched in "keratinocyte differentiation" of Module 1. The result was performed in boxplots, and we regarded  $p$  value  $< 0.05$  to have statistical significance.

## 3. Results

**3.1. Identification of DEGs and DEMs.** For the identification of DEGs between primary melanoma samples and metastatic melanoma samples, through applying limma software




FIGURE 2: GO functions for the 239 DEGs: (a) enriched biological process of the negatively regulated genes; (b) enriched cellular component of negatively regulated genes; (c) enriched molecular function of negatively regulated genes.

package, we conducted a differential expression analysis. Totally, we identified 1300, 731, and 1829 DEGs to be significantly differentially expressed from GSE46517, GSE7553, and GSE8401, respectively. Finally, we screened out 239 genes in all 3 datasets, which were inclusive of 21 positively regulated genes and 218 negatively regulated genes in metastatic melanoma tissues in comparison with primary melanoma tissues (Figure 1). Meanwhile, we identified 63 DEMs from the seven miRNA expression profiles, which

were made up of 35 positively negatively regulated miRNAs and 28 negatively regulated miRNAs in metastatic melanoma tissues in comparison with primary melanoma tissues (Table S1).

3.2. *Functional Enrichment Analysis.* We performed the functional enrichment analysis by making use of downregulated DEGs because the number of the DEGs (218/239) was large. We performed three categories of GO functional




FIGURE 3: Protein-protein interaction network of DEGs. Green nodes stand for negatively regulated genes in melanoma metastasis tissue. Red nodes stand for positively regulated genes in melanoma metastasis tissue.




FIGURE 4: Significantly enriched GO terms for modules: (a) enriched BP, CC, and MF for Module 1; (b) enriched BP, CC, and MF for Module 2.




FIGURE 5: DEM-DEG pair network. Green nodes stand for negatively regulated genes or negatively regulated miRNA in melanoma metastasis tissue. Red nodes stand for positively regulated genes or positively regulated genes miRNA in melanoma metastasis tissue.

annotation analysis on DEGs, including BP, CC, and MF. The GO BP analysis results presented that negatively regulated DEGs were obviously abundant in epidermis develop-

ment, keratinocyte differentiation, and keratinization (Figure 2(a), Table S2). The GO CC analysis showed that negatively regulated DEGs were abundant in extracellular

exosome and desmosome (Figure 2(b), Table S2). The GO MF analysis results presented that negatively regulated DEGs were obviously abundant in structural molecule activity and structural constituent of cytoskeleton (Figure 2(c), Table S2). We only identified 2 KEGG pathways, considerably enhancing in the amoebiasis signaling pathway and arrhythmogenic right ventricular cardiomyopathy (ARVC) pathway (Table S2).

**3.3. Construction and Analysis of PPI Network.** We performed the PPI network analysis of 239 DEGs through the STRING database, and 225 protein interactions with combined scores  $> 0.7$  were identified (Figure 3). We identified three modules by making use of MCODE plugin, an app in Cytoscape. Module 1 was constructed with 21 nodes and 209 edges including DSC1, DSC2, and DSC3. Module 2 was made up of 9 nodes and 32 edges, which were inclusive of KRT2, KRT6B, and KRT8. Module 3 includes 7 nodes and 12 edges, which were made up of KRT1, KRT5, KRT6A, and so on. Furthermore, we performed DEGs' functional enrichment analysis in these 3 modules. The results demonstrated that Module 1 was enriched in the keratinocyte differentiation, extracellular exosome (Figure 4(a), Table S3), and so on in GO analysis. Module 2 was enriched in epidermis development, extracellular exosome (Figure 4(b), Table S3), and so on in GO analysis. Module 3 was enriched in epidermis development in GO analysis (Table S3). Unfortunately, we did not identify significant KEGG pathways in all three modules ( $FDR < 0.01$ ).

**3.4. Prediction of DEM Target Gene and Construction of DEM-DEG Network.** We predicted 816 genes in total would be regulated by the 63 miRNAs identified above through making use of the TargetScan, PITA, and miRanda database. Among the 816 genes, 92 genes were overlapped with DEGs, being made up of 11 upregulated genes targeted by 11 negatively regulated DEMs and 81 genes downregulated genes targeted by 15 positively regulated DEMs. We presented the results in detail in Table S4.

Subsequently, as presented in Figure 5, the DEM-DEG network was constructed by Cytoscape software. We found that hsa-miR-181b [24], hsa-miR-211 [25, 26], and hsa-miR-24 [27, 28], which had the most potential target genes, had a paramount influence on melanoma progression and metastasis.

**3.5. Validation of Differential Expression of Metastasis-Associated Genes.** As shown in Table S3, Module 1 was obviously enriched in the keratinocyte differentiation in GO analysis. Until now, there were no detailed studies on keratinocyte differentiation in melanoma metastasis. As a result, we evaluated the expression of 11 enriched genes in keratinocyte differentiation through making use of the UALCAN database, including LOR, EVPL, SPRR1A, FLG, SPRR1B, SPRR2B, TGM1, DSP, CSTA, CDSN, and IVL (Figure 6). The analytic results demonstrated that all of the 11 genes were significantly downregulated in metastatic melanoma tissue in




FIGURE 6: Validation of differential expression of metastasis-associated genes in Module 1. Expression level of LOR, EVPL, SPRR1A, FLG, SPRR1B, SPRR2B, TGM1, DSP, CSTA, CDSN, and IVL in metastasis melanoma ( $n = 368$ ) and primary melanoma ( $n = 104$ ) based on data from TCGA. Notes:  $*p < 0.01$ .

comparison to primary melanoma tissue. Some of the genes, such as LOR, SPRR1B, and IVL, were even undetectable in metastatic melanoma tissue.

## 4. Discussion

Poor outcome of melanoma is primarily caused by metastasis. The reason for melanoma metastasis is still poorly understood to date. The more we know about the pathogenesis of metastasis, the better the drug can be developed and this disease can be treated. More and more evidence demonstrated that gene expression profiling analysis is of great use for humans to study the cancer progression and metastasis. We have also identified an abundance of genes involved in many crucial cellular pathways of cancer progression and found their expression in melanoma was aberrant.

The value of studies on metastasis-associated genes for melanoma by gene expression profiling is relatively limited to date. In this research, we collected gene expression profiling datasets of melanoma and made a systemic meta-analysis to retrieve genes in association with metastasis. We identified 239 DEGs in total. Many of them were known to take part in various cancer types. For example, DIO2 was underexpressed in nearly all papillary thyroid carcinomas and known as a latent target for thyroid tumor treatment [29, 30]. FGF1P1 was identified as a prometastasis gene in HCC [31], whereas S100 family genes' expressions, particularly S100A7, were high in primary melanoma samples but low in metastatic melanoma. S100A7's expression was in relation to tumor invasion, and it may enhance melanoma's early diagnosis [32–34]. Additionally, it has been suggested that many predicted targets of DEGs were associated with cancer development. Interestingly, we found that most of the DEGs were downregulated (218/239). We identified DEGs' expression in TCGA database, and the results were the same as our analysis. But the reason is unknown.




FIGURE 7: The reactome pathway diagram of the function of DEGs in Module 1 in keratinocyte differentiation.

Furthermore, we finished constructing the PPI network based on the DEGs. What is more, GO and KEGG pathway enrichment analyses were to further interpret their biological functions. For example, we found that 11 DEGs were enriched in keratinocyte differentiation GO term and close relation to melanoma metastasis (Figure 7). We found LOR, EVPL, SPRR1A, FLG, DSP, and CSTA had been reported in previous studies on melanoma [14, 27, 35–39]. But the report of SPRR1B, SPRR2B, TGM1, CDSN, and IVL in melanoma was a gap. Overall, this systematic meta-analysis of gene profiling was a step forward in the investigation of the mechanisms underlying melanoma’s metastasis, and the role of SPRR1B, SPRR2B, TGM1, CDSN, and IVL in keratinocyte differentiation GO term needs to be further studied.

This study has some limitations. First, the expression levels of genes related to keratinocyte differentiation were not verified by qRT-PCR. Secondly, the role of miRNA-mRNA in melanoma metastasis needs further experimental verification. In future research, we will carry out these explorations.

To sum up, we finished the identification of many biological genes, which may take part in melanoma’s metastasis, by collecting the gene expression datasets from the open database. This work identified keratinocyte differentiation-involved genes’ role in melanoma metastasis for the first

time, offering additional insights into this disease’s complicated process.

### Data Availability

All data analyzed during this study are obtained from published article or are available from the corresponding author on reasonable request.

### Consent

Consent is not applicable.

### Conflicts of Interest

The authors declare that they have no competing interests.

### Authors’ Contributions

NX designed the study. KL, SG, ST, and QS performed the study and drafted the article. KL, SJ, BQ, and YS conducted data acquisition, data analysis, and interpretation. All authors discussed the results and agreed to be accountable for all aspects of the work. All authors read and approved the final manuscript.

## Acknowledgments

This study was supported by the National Natural Science Foundation of China (51872332).

## Supplementary Materials

*Supplementary 1.* Table S1: differentially expressed miRNAs (DEMs) in melanoma.

*Supplementary 2.* Table S2: significantly enriched GO terms and KEGG pathways (downregulated).

*Supplementary 3.* Table S3: significantly enriched GO terms for modules.

*Supplementary 4.* Table S4: prediction of target genes for DEMs.

## References

- [1] M. McComiskey, C. Iavazzo, M. Datta et al., “Balloon cell urethral melanoma: differential diagnosis and management,” *Case Reports in Obstetrics and Gynecology*, vol. 2015, Article ID 919584, 4 pages, 2015.
- [2] H. E. Kanavy and M. R. Gerstenblith, “Ultraviolet radiation and melanoma,” *Seminars in Cutaneous Medicine and Surgery*, vol. 30, no. 4, pp. 222–228, 2011.
- [3] F. K. Bakkal, A. Başman, Y. Kızıl et al., “Mucosal melanoma of the head and neck: recurrence characteristics and survival outcomes,” *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology*, vol. 120, no. 5, pp. 575–580, 2015.
- [4] S. C. Azoury and J. R. Lange, “Epidemiology, risk factors, prevention, and early detection of melanoma,” *The Surgical Clinics of North America*, vol. 94, no. 5, pp. 945–962, 2014.
- [5] W. R. Shaikh, S. W. Dusza, M. A. Weinstock, S. A. Oliveria, A. C. Geller, and A. C. Halpern, “Melanoma thickness and survival trends in the United States, 1989–2009,” *Journal of the National Cancer Institute*, vol. 108, no. 1, 2016.
- [6] W. Chien, Q. Y. Sun, K. L. Lee et al., “Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer,” *Molecular Oncology*, vol. 9, no. 4, pp. 889–905, 2015.
- [7] S. Tabariès, V. Ouellet, B. E. Hsu et al., “Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases,” *Breast Cancer Research*, vol. 17, no. 1, p. 45, 2015.
- [8] N. Hu, R. J. Clifford, H. H. Yang et al., “Genome wide analysis of DNA copy number neutral loss of heterozygosity (CNNLOH) and its relation to gene expression in esophageal squamous cell carcinoma,” *BMC Genomics*, vol. 11, no. 1, p. 576, 2010.
- [9] F. Fu, X. Wan, D. Wang et al., “MicroRNA-19a acts as a prognostic marker and promotes prostate cancer progression via inhibiting VPS37A expression,” *Oncotarget*, vol. 9, no. 2, pp. 1931–1943, 2018.
- [10] J. Ding, X. Zhu, X. Chen, J. Guan, and H. Li, “MicroRNA-182 suppresses malignant melanoma proliferation by targeting RECK,” *Clinical Laboratory*, vol. 66, 2020.
- [11] Y. Wang, Z. Ou, Y. Sun et al., “Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals,” *Oncogene*, vol. 36, no. 12, pp. 1644–1654, 2017.
- [12] J. Y. Li, L. L. Zheng, T. T. Wang, and M. Hu, “Functional annotation of metastasis-associated microRNAs of melanoma,” *Chinese Medical Journal*, vol. 129, no. 20, pp. 2484–2490, 2016.
- [13] O. Kabbarah, C. Nogueira, B. Feng et al., “Integrative genome comparison of primary and metastatic melanomas,” *PLoS One*, vol. 5, no. 5, article e10770, 2010.
- [14] A. I. Riker, S. A. Enkemann, O. Fodstad et al., “The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis,” *BMC Medical Genomics*, vol. 1, no. 1, p. 13, 2008.
- [15] L. Xu, S. S. Shen, Y. Hoshida et al., “Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases,” *Molecular Cancer Research*, vol. 6, no. 5, pp. 760–769, 2008.
- [16] M. K. Kerr, “Linear models for microarray data analysis: hidden similarities and differences,” *Journal of Computational Biology*, vol. 10, no. 6, pp. 891–901, 2003.
- [17] M. Ashburner, C. A. Ball, J. A. Blake et al., “Gene Ontology: tool for the unification of biology,” *Nature Genetics*, vol. 25, no. 1, pp. 25–29, 2000.
- [18] M. Kanehisa and S. Goto, “KEGG: Kyoto Encyclopedia of Genes and Genomes,” *Nucleic Acids Research*, vol. 28, no. 1, pp. 27–30, 2000.
- [19] D. W. Huang, B. T. Sherman, Q. Tan et al., “The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists,” *Genome Biology*, vol. 8, no. 9, p. R183, 2007.
- [20] P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” *Genome Research*, vol. 13, no. 11, pp. 2498–2504, 2003.
- [21] V. Agarwal, G. W. Bell, J. W. Nam, and D. P. Bartel, “Predicting effective microRNA target sites in mammalian mRNAs,” *eLife*, vol. 4, 2015.
- [22] B. John, A. J. Enright, A. Aravin, T. Tuschl, C. Sander, and D. S. Marks, “Human microRNA targets,” *PLoS Biology*, vol. 2, no. 11, article e363, 2004.
- [23] M. Kertesz, N. Iovino, U. Unnerstall, U. Gaul, and E. Segal, “The role of site accessibility in microRNA target recognition,” *Nature Genetics*, vol. 39, no. 10, pp. 1278–1284, 2007.
- [24] A. A. Dar, S. Majid, C. Rittsteuer et al., “The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression,” *Journal of the National Cancer Institute*, vol. 105, no. 6, pp. 433–442, 2013.
- [25] C. Margue, D. Philippidou, S. E. Reinsbach, M. Schmitt, I. Behrmann, and S. Kreis, “New target genes of MITF-induced microRNA-211 contribute to melanoma cell invasion,” *PLoS One*, vol. 8, no. 9, article e73473, 2013.
- [26] M. Díaz-Martínez, L. Benito-Jardón, L. Alonso, L. Koetz-Ploch, E. Hernando, and J. Teixidó, “miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma,” *Cancer Research*, vol. 78, no. 4, pp. 1017–1030, 2018.
- [27] M. Sand, M. Skrygan, D. Sand et al., “Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi,” *Cell and Tissue Research*, vol. 351, no. 1, pp. 85–98, 2013.
- [28] Y. Xiao, Q. Diao, Y. Liang, Y. Peng, and K. Zeng, “MicroRNA-24-1-5p promotes malignant melanoma cell autophagy and



- apoptosis via regulating ubiquitin D,” *Molecular Medicine Reports*, vol. 16, no. 6, pp. 8448–8454, 2017.
- [29] A. B. Santoro, D. D. Vargens, M. C. Barros Filho et al., “Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer,” *British Journal of Clinical Pharmacology*, vol. 78, no. 5, pp. 1067–1075, 2014.
- [30] L. A. Arnaldi, R. C. Borra, R. M. B. Maciel, and J. M. Cerutti, “Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors,” *Thyroid*, vol. 15, no. 3, pp. 210–221, 2005.
- [31] W. Huang, Z. Chen, X. Shang et al., “Sox12, a direct target of FoxQ1, promotes hepatocellular carcinoma metastasis through up-regulating Twist1 and FGFBP1,” *Hepatology*, vol. 61, no. 6, pp. 1920–1933, 2015.
- [32] S. Petersson, E. Shubbar, L. Enerbäck, and C. Enerbäck, “Expression patterns of S100 proteins in melanocytes and melanocytic lesions,” *Melanoma Research*, vol. 19, no. 4, pp. 215–225, 2009.
- [33] M. C. Brouard, J. H. Saurat, G. Ghanem, and G. Siegenthaler, “Urinary excretion of epidermal-type fatty acid-binding protein and S100A7 protein in patients with cutaneous melanoma,” *Melanoma Research*, vol. 12, no. 6, pp. 627–631, 2002.
- [34] T. F. Xiong, F. Q. Pan, and D. Li, “Expression and clinical significance of S100 family genes in patients with melanoma,” *Melanoma Research*, vol. 29, no. 1, pp. 23–29, 2019.
- [35] G. Boike, T. Lah, B. F. Sloane et al., “A possible role for cysteine proteinase and its inhibitors in motility of malignant melanoma and other tumour cells,” *Melanoma Research*, vol. 1, no. 5, pp. 333–340, 1992.
- [36] E. P. Salerno, D. Bedognetti, I. S. Mauldin et al., “Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk,” *Oncoimmunology*, vol. 5, no. 12, article e1240857, 2016.
- [37] J. P. Thyssen, Y. M. F. Andersen, E. Balslev et al., “Loss-of-function mutations in filaggrin gene and malignant melanoma: a case-control study,” *Journal of the European Academy of Dermatology and Venereology*, vol. 32, no. 2, pp. 242–244, 2018.
- [38] A. Yayon, Y. S. Ma, M. Safran, M. Klagsbrun, and R. Halaban, “Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: evidence for the involvement of Src-family kinases,” *Oncogene*, vol. 14, no. 25, pp. 2999–3009, 1997.
- [39] L. X. Wang, Y. Li, and G. Z. Chen, “Network-based co-expression analysis for exploring the potential diagnostic biomarkers of metastatic melanoma,” *PLoS One*, vol. 13, no. 1, article e0190447, 2018.